Work

Long-Term Treatment With Interleukin-6 Receptor Inhibitor Tocilizumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Year: 2026

Type: article

Abstract: Data about efficacy and safety of disease-modifying therapeutic options in myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) are scarce. Interleukin-6 signaling has been suggested to be involved in the pathogenesis of MOGAD. The aim of this study was to evaluate the effectiveness and safety of the interleukin-6 receptor inhibitor tocilizumab (TCZ) in MOGAD.

Source: Neurology Open Access

DOI: 10.1212/wn9.0000000000000049

Authors: Francesco Capecchi, Madalina Graure, Sinan Yasaroglu, Salome Schubert, Nathalie Nierobisch, Veronika Kana, Michael Weller, Patrick Roth, Marina Herwerth

Institutions: University Hospital Zurich, University of Zurich, ETH Zurich, TUM Klinikum, Technical University of Munich

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W7128426290

FWCI: 8.761

Cites: 31

Cited by: 2

Related to: